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Abstract: Neuroendocrine tumors of the lung (Lu-NETs) embrace a heterogeneous family of neoplasms 
classified into four histological variants, namely typical carcinoid (TC), atypical carcinoid (AC), large cell 
neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). Defining criteria on resection 
specimens include mitotic count in 2 mm2 and the presence or absence of necrosis, alongside a constellation 
of cytological and histological traits including cell size and shape, nuclear features and overall architecture. 
Clinically, TC are low-grade malignant tumors, AC intermediate-grade malignant tumors and SCLC/
LCNEC high-grade malignant full-blown carcinomas with no significant differences in survival between 
them. Homologous tumors arise in the thymus that occasionally have some difficulties in differentiating from 
the lung counterparts when presented with large unresectable or metastatic lesions. Immunohistochemistry 
(IHC) helps refine NE diagnosis at various anatomical sites, particularly on small-sized tissue material, in 
which only TC and small cell carcinoma categories can be recognized easily on hematoxylin & eosin stain, 
while AC and LCNEC can only be suggested on such material. The Ki-67 labeling index effectively separates 
carcinoids from small cell carcinoma and may prove useful for the clinical management of a metastatic 
disease to help the therapeutic decision-making process. Although carcinoids and high-grade neuroendocrine 
carcinomas in the lung and elsewhere make up separate tumor categories on molecular grounds, emerging 
data supports the concept of secondary high-grade NETs arising in the preexisting carcinoids, whose clinical 
and biological relevance will have to be placed into the proper context for the optimal management of these 
patients. In this review, we will discuss the selected, recent literature with a focus on current issues regarding 
Lu-NET nosology, i.e., classification, derivation and tumor evolution.
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Introduction
Neuroendocrine tumors of the lung (Lu-NETs) make 
up a heterogeneous family of neoplasms ranging from 
quite indolent lesions with long-term life expectancy to 
extremely aggressive tumors with very poor prognosis. 
The 2015 WHO classification has grouped the four 
histologic variants of Lu-NETs, namely typical carcinoid 
(TC), atypical carcinoid (AC), large cell neuroendocrine 
carcinoma (LCNEC) and small cell lung carcinoma 
(SCLC), into a unique box of neuroendocrine (NE) cell 
proliferations to facilitate their taxonomy and improve 
diagnostic recognition (1,2). Behaviorally, TC are low-
grade tumors with good prognosis usually cured by 
surgery alone, AC intermediate-grade tumors with a more 
aggressive clinical course benefitting from multimodality 
therapy, and LCNEC and SCLC high-grade full-
blown carcinomas with dismal prognosis usually treated 
by chemo-radiotherapy (1). Although tumor grading 
is included into the current classification scheme, as 
considerable clinical and epidemiologic data have been 
validating a pathologic four-tier, clinical three-tier 
spectrum of NE-differentiated tumors (1,3), a grading 
system independent of histology could prove useful in 
the setting of a metastatic disease and/or small-sized 
diagnostic material, where morphology alone could not 
match adequately with the pathologic and clinical grade to 
support the best therapy choices (4,5).
Tumors homologous with Lu-NENs arise in the 
thymus (T-NENs) and gastro-entero-pancreatic tract 
(GEP-NENs), likely due to their common origin from 
endoderm-derived precursors/stem cells of the foregut 
according to specific molecular gene pathway alterations 
(6-11). Significant differences, however, in the biological 
characteristics of these tumors make a direct comparison 
with Lu-NETs clinically unwarranted (12-23). Suffice it to 
say that a backbone observation regarding NENs is that 
they behave diversely according to the different anatomical 
sites (23,24), associated risk factors and underlying 
molecular mechanisms (24-29). However, differences in 
cell lineage or the diverse application of defining criteria 
may cause some inconsistency to arise in the diagnostic, 
prognostic and predictive interpretation (8-11). This 
bewildering situation becomes even more challenging and 
frustrating when dealing with metastatic NENs of unproven 
or uncertain origin and/or small-sized diagnostic material, 
where morphology alone may be a major pitfall in the 
management of tumor patients (5,30-36).
The classification of Lu-NETs is a stepwise process 
based on a constellation of cytological and histological 
traits alongside the evaluation of mitotic count and necrosis 
extent (1,2). At variance with its established role in GEP 
NENs according to existing guidelines (37,38) and the 
forthcoming 2017 WHO classification on non-pulmonary 
neuroendocrine tumors, immunohistochemistry (IHC) for 
NE markers is not strictly required to render an ultimate 
diagnosis of Lu-NETs. Nonetheless, it is recommended 
to confirm their NE nature and, particularly, to separate 
LCNEC from other histologic mimickers, such as large cell 
carcinoma with NE morphology (LCC-NEM) and basaloid 
carcinoma, or to identify combined variants with non-small 
cell carcinoma (NSCC) components (1,2).
Lung TC and AC as a whole are pragmatically equated 
to well-differentiated neoplasms in opposition to SCLC 
and LCNEC, which are collectively poorly differentiated 
tumors closest to the NE carcinoma (NEC) category of 
GEP NENs (3,8-11). This dichotomy of morphologic 
classification is consistent with the current assertion that 
TC and AC in the lung are molecularly distinct from 
SCLC and LCNEC (1,2,39-43). Major differences in the 
somatic mutation rate and engagement of diverse gene 
pathway alterations have been observed in these two main 
groupings of Lu-NETs (31,42-52); while there is some 
inter-tumor heterogeneity of molecular events within a 
category, particularly AC and LCNEC (39,40,53-55). 
These observations support the view that different patient 
subsets exist within each variant of Lu-NETs as defined 
upon histology, with some degrees of overlap among the 
categories (25,27), suggesting some commonality in their 
origin, developmental mechanisms, prognosis or treatment 
options (5,8,9,53-57).
Browsing the recent literature, this review is focused 
on current Lu-NETs nosology, immunophenotyping, 
proliferation indices and molecular alterations, trying 
to place into context all current information for the best 
management of the patients.
Diagnosis and classification of pulmonary 
neuroendocrine tumors
TC and AC in the lung retain morphologic criteria of 
well-differentiated NETs (1,3,58). They are close to the 
normal NE elements present in the respiratory mucosa, 
hyperplastic NE cells as seen in chronic inflammation 
and the diffuse idiopathic pulmonary NE cell hyperplasia 
(DIPNECH), a pre-invasive lesion with a potential 
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towards the development of carcinoids (1,59-61). Defining 
criteria of these tumors include organoid growth patterns 
(rosettes, trabeculae, ribbons, festoons, lobular nests, 
palisading), absent to focal punctate necrosis (not just 
apoptotic bodies), up to 10 mitoses per 2 mm2 and a 
consistent labeling for pan-NE IHC markers, sometimes 
less intense and uneven in AC (1,3,58,62,63). On the 
contrary, SCLC and LCNEC are clustered into poorly 
differentiated tumors showing trabecular to solid to 
diffuse growth patterns, extensive/geographic necrosis, 
mitotic count higher than 10 mitoses per 2 mm2 with no 
theoretical upper limit and uneven cell decoration for 
pan-NE markers, especially those based on dense-core 
granules (1,3,62-65). Tumor architecture and cytological 
details serve further to separate LCNEC from SCLC, 
even though inter-observer reproducibility remains 
disappointingly low (66-70). LCNEC is a tumor category 
defined upon pan-NE IHC markers to exclude histological 
mimics such as LCC-NEM and basaloid carcinoma, or 
identify non-NE components in combined variants (1,71). 
The diagnosis of SCLC in turn relies primarily upon 
morphology in both the lung and elsewhere, although 
IHC has been recommended to either reduce the rate of 
misdiagnosis in challenging cases for technical reasons or 
to increase the diagnostic confidence of pathologists for 
complex differential diagnoses (65).
In surgical as well as in biopsy/cytology specimens, 
general markers of NE differentiation provide a reliable 
profile for all histologic variants of Lu-NETs, while single 
hormones are less useful even in the metastatic setting 
or when facing with unknown origin lesions because 
of the lack of specific substances produced in the lower 
respiratory tract (72). Current guidelines and longstanding 
experience recommend using a couple of well-established 
pan-NE markers to cross the entire spectrum of Lu-NETs 
(1-3,65,73). Among plentiful pan-NE markers, the most 
currently used are cytoplasm-based molecules contained 
in dense core granules, such as chromogranin A, whose 
presence closely parallels the biogenesis of secretory 
granules and hence cell differentiation (74), or small clear 
synaptic vesicles, such as synaptophysin, which regulates 
the kinetics of synaptic vesicle endocytosis (75) and 
whose expression is still retained in high-grade Lu-NETs 
(1-3,65,73). As poorly differentiated Lu-NET down-
regulate chromogranin A, its expression should be evaluated 
at high-power magnification to appreciate even faint 
granular signals in scattered tumor cells (1). Embryonic 
nuclear determinants of NE differentiation in the lung, 
such as human achaete-scute homolog 1 (hASH1), are 
usually lost or poorly expressed in carcinoids but retained 
by high-grade tumors, especially SCLC (76,77), whereas 
membrane-based NCAM/CD56 is sensitive but less specific 
for NE differentiation (1,78). The latter is expressed in all 
Lu-NETs, especially SCLC (40,77-79), but can turn out 
positive also in conventional NSCC (80), various sarcomas 
(81,82) and malignant mesothelioma (83). High molecular 
weight keratins (CK), such as those recognized by the clone 
34βE12 (CK1, CK5, CK10 and CK14), are consistently 
negative in Lu-NETs (84). The squamous differentiation 
determinant DeltaNp63/p40 is unreactive in all variants 
of Lu-NETs (85), although its expression is found rarely 
in some LCNEC exhibiting morphology and molecular 
alterations more akin to SCLC (40). These tumors with 
focal (≤10% tumor cells) positivity for DeltaNp63/p40 but 
no overt squamous differentiation harbor a high prevalence 
of KEAP1-NFE2L2 alterations, suggesting that they are 
somewhat linked to squamous cell carcinoma rather than 
conventional SCLC (40).
Another nuclear determinant of NE differentiation, 
i.e., insulinoma-associated protein 1 (INSM1), has 
recently been proposed to stain consistently all variants 
of Lu-NET regardless of histology, but not conventional 
adenocarcinoma or squamous cell carcinoma (86,87). This 
marker is potentially expected to work better than the usual 
pan-NE antigens because of its wide range of expression 
across the entire spectrum of Lu-NETs, and could become 
a reference molecule for NE differentiation in the near 
future. In general, nuclear markers are less likely affected 
by cellular damage, thus remain intact on small-sized and/
or crushed tissue samples, while organelle- or membrane-
associated markers may suffer from non-specific staining 
due to extracellular extravasation or may not consistently 
reflect their own locations in the cytoplasm (88). Albeit rare 
in the lung but less in the mediastinum, nuclear in testis 
(NUT) midline carcinoma (NMC) (88,89), Ewing sarcoma 
family (ESF) (90) and desmoplastic small round cell 
tumor (DSRCT) (91) should also be accounted for in the 
differential diagnosis of high-grade NETs especially when 
facing with large unresectable or metastatic lesions, due 
to close similarities in histologic appearance and striking 
overlap of IHC markers with more conventional thoracic 
NETs. In this regard, an appropriate IHC for NUT protein 
in NMC and specific molecular investigation for diagnostic 
translocations in ESF and DSRCT allow the correct 
diagnosis to be rendered in most cases with high rate of 
confidence.
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Identifying the origin of neuroendocrine tumors
The identification of thoracic NEN origin plays an 
important role in adopting the most appropriate terminology, 
correctly classifying metastatic tumors and offering the 
best therapeutic options (1,2,92), given that lung and 
thymus NETs differ in tumor presentation (7,12,14), 
associated endocrine syndromes (12,13,16,18,19,21,93,94), 
underlying risk factors (1,15) and molecular alterations 
(1,95). The differentiation of Lu-NETs from T-NETs 
proves to be particularly challenging in the setting of low- 
to intermediate-grade tumors displaying large unresectable 
or metastatic lesions at the time of diagnosis (96). Whether 
IHC is able to play some role in this task is outlined below.
Thyroid transcription factor-1 (TTF-1) is a useful 
marker of pulmonary lineage only when positive in 
the group of well-differentiated NETs. Of note, only 
a minority of well-differentiated Lu-NETs, especially 
those composed of spindle cells arising from peripheral 
bronchioles, are TTF-1 positive (1,97-102), so as some 
of DIPNECH or NE cell hyperplasia of the lung (103). 
The main limitation to the use of this marker in high-
grade NECs as a descriptor of lung origin is that most of 
them demonstrate a diffuse reactivity regardless of their 
pulmonary or extra-pulmonary derivation (1,102,104). 
Moreover, some T-NETs (93) may be reactive for TTF-1 
even when using the most specific clone 8G7G3/1, 
thus TTF-1 may not be a reliable maker to confirm 
the pulmonary origin in thoracic NETs. Many other 
nuclear transcription factors, which are frequently used to 
differentiate well differentiated NETs in diverse organs, 
namely Islet-1 (103,105,106), PAX-8 (101,105) and 
CDX2 (106),  can be aberrantly and il legitimately 
expressed in high-grade NETs regardless of their 
anatomical locations (31,107). Similarly, CD117 does 
not separate reliably lung from thymic NETs because 
is often expressed in both anatomical compartments, 
especially less differentiated lesions (1,108,109) as well as 
conventional NSCC (110) and thymic carcinoma (1,92). 
Conversely, CD5 expression is exceedingly rare in NETs 
of either anatomical site (23), while CD5 reacts with about 
a half of thymic squamous cell carcinomas (1,92,111) and 
a non-negligible fraction of NSCLC (112). Potential 
confounding factor is represented by combined variants of 
NETs not only at the level of the IHC characterization (due 
to co-expression of unexpected profiles and lack of protein 
expression characteristic of either tumor type), but also at 
the molecular level (113). It has recently been noted that 
mixed NE/non-NE carcinomas are molecularly different 
from their pure NE and non-NE counterparts in the lung 
and a variety of extra-pulmonary sites when analyzed for 
cDNA quantification of ribonucleotide reductase, large 
subunit 1, excision repair cross-complementation group 
1 and thymidylate synthase (114). In this setting of a 
predominant non-NE component, the administration 
of adjuvant therapy in addition to surgery and a high 
thymidylate synthase expression in non-NET components 
were significantly associated with a lower risk of patient 
death, thereby improving the clinical strategies for the 
treatment of these rare and underestimated tumors (114).
The role of IHC becomes particularly relevant in the 
scenario of small biopsy or cytology samples, where it is 
clinically warranted to separate NE from other non-NE 
tumors or unrelated malignancies mimicking NETs in 
either the lung or thymus. In a recent international study 
carried out on biopsy samples, the rate of agreement on 
SCLC diagnosis was increased from 64.7% obtained by 
the solely morphology to 77.5% with a judicious use of a 
variety of IHC markers, such as cytokeratin cocktail, pan-
NE markers, TTF1, p16 (expressed by high-grade NETs, 
especially SCLC), retinoblastoma protein and Ki-67 
antigen, with Cohen’s kappa coefficient scores on IHC 
being 0.60 and 0.64 in resected specimens and biopsy 
samples, respectively (65). While the differentiation of 
SCLC from other unrelated mimics (undifferentiated 
carcinomas, small cell sarcomas or lymphomas) requires 
further IHC markers and molecular assays, the single most 
reliable marker in NETs to get insights into their clinical 
behavior remains the Ki-67 antigen (1,30,115). This marker 
is particularly reliable on small biopsy or cytology samples 
in the presence of scarce material or crush artifacts (32).
Identifying the clinical aggressiveness of 
neuroendocrine tumors and the role of Ki-67 
antigen
Ki-67 antigen has been extensively evaluated in Lu-NET 
with several diagnostic, prognostic and grading implications 
[reviewed in (115)]. Since the Ki-67 antigen identifies 
proliferating cells spanning from G1 to M phase (116-118), 
Ki-67 nuclear expression is proportional to the mitotic 
count, but reveals more proliferating tumor cells than the 
latter, which remains the backbone of defining criteria in 
Lu-NETs and T-NETs according to existing guidelines (1). 
The method to quantify Ki-67 expression and that 
to count mitoses are different; a percentage of Ki-67 
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positive cells (labeling index, LI) is usually obtained in 
hot spot regions with highest staining, while the mitotic 
count is based on the number of mitotic figures in pre-
defined tumor areas of highest activity (high power fields or 
square millimeters). The difference may account in part for 
inconsistent results between these proliferation indexes (4). 
Indeed, once mitoses are expressed as mitotic index 
rather than mitotic count (119), the correlation rate with 
Ki-67 LI increases considerably (120,121). Furthermore, 
another source of inconsistency is the alleged lack of 
inter-observer reproducibility of Ki-67 LI, which is likely 
attributed to the differences in regions (randomly selected 
fields; hot spot areas of highest labeling; entire tumor 
area) and methods (few hundreds to thousands of tumors 
cells; eyeball, manual or picture-based count evaluation or 
automated analysis system adoption) for counting Ki-67 
positive tumor cells, once pre-analytical issues (fixation, 
staining systems, reagents) are equated (8,115,122-124). 
Another conundrum is the intra-tumor heterogeneous 
distribution of Ki-67 antigen likely due to the unpredictable 
occurrence of differentially regulated tumor cell subsets in 
tumors (115,120), but the consistent assessment of labeling 
indexes in hot spot regions will lead to more reproducible 
results (115). This biological phenomenon becomes 
particularly challenging on biopsy/cytology specimens in 
comparison with resection specimens (30,33,125) because 
of unpredictable sampling issues (the so-called tip-of-the-
iceberg effect or the part of the whole). Therefore, the 
reproducibility and clinical usefulness of Ki-67 LI in Lu-
NETs have been seriously argued, with alleged superiority 
of mitotic count, which has remained the only proliferation 
criterion in tumor classifications over time (1,126,127), 
with no current diagnostic role for Ki-67 (1). However, 
reproducibility of results for Ki-67 LI is not worse than any 
other IHC markers when tested for quantification (128,129) 
and even mitotic count shows large inter-observer variability 
in Lu-NETs classification of either carcinoids (130) 
or high-grade tumors (66-70). The only obvious difference 
is that mitotic count is traditional, largely known by 
pathologists everywhere and carried out simultaneously 
with hematoxylin-eosin diagnosis, whereas Ki-67 antigen 
evaluation requires additional IHC on new paraffin sections 
and a numeric quantification. Hopefully, the localization 
of the same tumor areas as those assessed for mitotic count 
will make results biologically more reasonable (115). Last 
but not least, the unavailability of IHC in some pathology 
laboratories would prefer mitotic count over Ki-67 LI 
in the daily practice. In any event, Ki-67 LI should not 
be used as a surrogate of mitotic count, since it is not a 
current defining criterion, but rather a complementary 
tool. In contrast, Ki-67 LI is a backbone of the grading 
system of GEP tract NENs, once tumors are split into well 
differentiated and poorly differentiated categories based on 
morphological grounds (8-11,37,131).
A recent standardization of Ki-67 LI on biopsy 
samples and the corresponding surgical specimens of 
Lu-NETs have demonstrated that results were quite 
superimposable with minimal deviation, even among 
different observers, provided that precise methodology 
rules were a priori established and used in either type of 
material (30). In keeping with other comparative studies 
(33,125), it was important to start identifying hot spot 
regions in either type of material in order to obtain 
overlapping results when counting 2,000 cells, 2-mm2-
spanning areas or the entire biopsy fragment(s) (30). 
In this way, it was possible to attribute to unpredictable 
sampling, tissue sizing, intra-tumor heterogeneous 
distr ibution of  Ki-67 antigen and inter-observer 
discordance when Ki-67 LI were discrepant between 
biopsies and the corresponding resection specimens (30). 
This study also suggests that different methods for the Ki-67 
LI assessment but not an inherent unreliability of the marker 
as a biological predictor affect its clinical meaning (30). 
Recent reproducibility studies in Lu-NET have revealed 
that there is less than 1.5% of variability when evaluating 
Ki-67 LI, with an out-performance over mitotic count with 
regard to inter-observer agreement (132,133). 
Although Ki-67 LI is not currently accredited with Lu-
NET subtyping due to some overlap of cut-off thresholds 
among biologically adjacent tumors (TC vs. AC, AC vs. 
LCNEC, LCNEC vs. SCLC), its differential distribution 
between low- to intermediate-grade and high-grade tumors 
has made it an irreplaceable discriminator especially on 
biopsy/cytology samples, and recommended even on 
surgical specimens (1,32,115). A Ki-67 LI up to 20–25% 
has the highest specificity and sensitivity for low- to 
intermediate-grade versus high-grade tumors, whilst other 
IHC markers or a combination of necrosis and mitotic count 
have lower specificity and sensitivity (1,30,32,115). Given 
the reported prognostic role of the Ki-67 LI within the same 
group, such as TC and/or AC, Ki-67 LI has emerged as a 
reliable criterion for clinical decision-making (132,134-137), 
in particular, in the setting of metastatic disease. It is 
important to note that Ki-67 LI closely reflects tumor 
biology, while the role of the more fallacious morphology 
is limited in small-sized and/or crushed diagnostic 
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materials (138). Such an advantage holds particularly 
true for AC and LCNEC, the most clinically challenging 
categories of Lu-NETs likely due to the large range 
of diagnostic criteria (2–10 mitoses in AC; no upper 
limit over 10 mitoses alongside a wide spectrum of 
morphology for LCNEC) (1,40,66,67,69,139). Conversely, 
diagnostic criteria for TC (virtual absence of mitosis 
and necrosis) and SCLC (undifferentiated morphology, 
plentiful mitoses, extensive/geographic necrosis) are 
consistent with biologically and behaviorally more 
homogeneous categories that occupy the ends of the 
Lu-NET spectrum (1,73). Not unexpectedly, Ki-67 
is typically 5% or less in TC and usually 80% or more in 
SCLC (118). Our recent observations showed that AC with 
Ki-67 LI of 10% or more consisted of tumors with more 
prominent proliferation activity within the allowed range of 
mitotic count and necrosis, and are associated with worse 
prognosis than predicted within the tumor category (140). It 
has also been noted that LCNEC with molecular alterations 
akin to NSCLC or AC feature the mean Ki-67 LI lower 
than that of LCNEC with molecular alterations similar to 
SCLC (i.e., SCLC-like LCNEC), which in turn feature 
cytomorphology in the SCLC spectrum (40). Other studies 
have revealed that AC behaviorally can overlap with either 
TC, SCLC or LCNEC when using Ki-67 LI thresholds 
specifically designed for the lung (4).
As necrosis and mitoses are unreliable criteria on biopsy 
samples (1,3,30,58), the differentiation of TC from AC or 
the diagnosis of LCNEC is usually not permissive on the 
morphologic basis alone or can only be suggested in these 
samples (1,141). In Lu-NETs, the main clinical question 
concerns the need of the patient risk stratification on the 
basis of tumor aggressiveness, especially in the setting of 
metastatic disease where the morphology on small-sized 
diagnostic materials could be misleading (5,138). Therefore, 
together with the overall clinical profiles (radiology and 
nuclear medicine imaging, tumor burden, symptoms 
and individual risk for evolving disease) Ki-67 LI could 
potentially be a decisional factor to stratify patients into 
more defined clinical categories for precision medicine (5).
Accordingly, metastatic Lu-NETs can be stratified into 
four main clinical groups by integrating Ki-67 LI and 
traditional histology (5).
(I) The first group consist of completely indolent 
tumors showing Ki-67 LI of 5% or less, which 
biologically correspond to either TC or AC with 
a low mitotic count and could be treated with 
biological drugs (somatostatin analogues or m-TOR 
pathway inhibitors), if any (3,58).
(II) The second group includes low-to-moderate 
malignant tumors showing Ki-67 LI up to 20–25%, 
which biologically correspond to rare TC, most AC 
and even some LCNEC with a molecular profile 
similar to that of carcinoids (40). They are probably 
managed still with biological drugs and/or peptide 
receptor radionuclide therapy alone (142-144), 
though no official guidelines yet exist for them 
(3,58,145,146).
(III) The third group consists of moderate to higher 
malignant tumors with Ki-67 LI ranging from 
25% to 50–60%, biologically corresponding to 
more uncommon aggressive AC or LCNEC with 
a molecular profile similar to that of NSCLC (40). 
They can be treated with alkylating drugs or 
others but not with platinum/etoposide-based 
chemotherapy, such as gemcitabine, paclitaxel or 
vinorelbine (93,144).
(IV) The last group is composed of highly malignant 
tumors with Ki-67 LI ranging from 60% to 100%, 
biologically corresponding to aggressive SCLC and 
SCLC-like LCNEC on molecular grounds (41), 
which should be treated with platinum/etoposide-
based chemotherapy (1,144).
Phenotypic/genotypic correlations in Lu-NET showed 
that a Ki-67 LI over 10% predicts poor prognosis within the 
AC category outperforming necrosis and mitotic count (140) 
and that there is a close relationship between proliferation 
activity and molecular subcategorization of LCNEC (40). 
For the latter, LCNEC exhibiting a molecular profile 
similar to that of SCLC had the highest Ki-67 LI (on average 
90%), LCNEC harboring NSCLC-like mutations displayed 
an intermediate value around 60% and those bearing 
MEN1 mutations presented with the lowest Ki-67 LI 
around 35% (40). This peculiar distribution of Ki-67 LI as 
a function of cell morphology and differentiation levels is 
similar to what has recently been described in the digestive 
system under the new classification of GEP NEN tumors, 
which, along with NET G1 and G2, now includes NET G3, 
distinct from (poorly differentiated) NEC (144).
Neuroendocrine tumors and molecular 
alterations
It is widely accepted that Lu-NETs and T-NETs consist 
of biologically distinct groups but not a continuum of 
neoplasms with common pathogenesis (1,50,92). In both 
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anatomical sites, TC/AC on the one hand and LCNEC/
SCLC on the other prove separate malignancies when 
molecularly dissected, with recurrent and non-random 
alterations of cell cycle checkpoints, chromatin remodeling 
and recurrent chromosomal alterations (1,50,92,95). 
Whether genetic traits are better than morphology or IHC 
markers to distinguish lung from thymus NENs, especially 
in the setting of large tumors occupying both anatomical 
regions and metastatic sites, still remains as an unanswered 
question due to the lack of organ-specific profiles.
TC and AC in the lung (42,44-46,48,50,55,115,147) and 
the homologous G1-G2 NETs in the GEP tract (24,148) (data 
thus far are largely unavailable for T-NETs) display lower 
somatic mutation rates (<1 per million base pairs) compared to 
the high-grade counterparts likely due to substantial differences 
in risk factors (1,149-151), gene pathway activations, levels 
of differentiation and purported cell derivation (42,44-
46,48,50,55,115,147). In the lung, defined candidate driver 
alterations are identifiable in up to 73% of TC and AC (42). 
Briefly, RB1 and TP53 mutations are quite uncommon in TC 
and AC (152), whereas inactivation of genes affecting histone 
methylation (MEN1) by multiple mechanisms and SWI/SNF 
complex subunit mutations (ARID1A, SMARC1, SMARCA2, 
SMRCA4) are found in up to one third of cases (42,50-52,55). 
Additional alterations include mutations of CBX6, EZH2, 
EIF1AX and E3 ubiquitin ligases (52).
Among high-grade Lu-NETs, LCNEC constitute a 
heterogeneous family of tumors, with some of them being 
classified SCLC-like LCNEC accounting for about 40%, 
NSCLC-like LCNEC (either adenocarcinoma or squamous 
cell carcinoma) accounting for about 50% and carcinoid-
like LCNEC accounting for about 5% on the basis of the 
different sets of altered genes (40). SCLC-like LCNEC 
share molecular alterations with SCLC and show RB1, 
TP53, CREBBP, EP300 and MLL gene mutations (40,42,49) 
alongside MYCL1 and FGFR1 amplifications. NSCLC-like 
LCNEC exhibit CDKN2A deletion, TTF1 amplifications 
and KEAP1 and STK11 mutations as observed in non-NE 
tumors (40,42,49) and carcinoid-like LCNEC bear MEN1 
mutations (40,153). SCLC has one of the highest mutation 
rates in cancers, with inactivating mutations of tumor 
suppressor genes (TP53, RB1) and chromatin remodeling 
genes (CREBBP, EP300, MLL) being more frequently found 
(42,46,154). Other recurrent gene aberrations include 
mutations of PTEN, SLIT2, COBL, EPHA7 and CDKN2A 
genes, along with amplification of FGFR1, MYCL1, MYCN, 
MYC, SOX2, KIAA1432, RICTOR, JAK2 and MAD1L1 
(42,44,46,48,154-157) and recurrent fusion transcript 
RLF-MYCL1 (44,48). Inactivation of NOTCH gene upon 
mutation with simultaneous ASCL1 and canonical WNT 
signaling engagement in addition to mutual bi-allelic RB1 
and TP53 lesions is at the basis of pulmonary and extra-
pulmonary small cell carcinoma developing as secondary 
tumors from preexisting non-NE carcinomas, either 
spontaneous or induced by therapy (158). Activation of 
epithelial-mesenchymal transition (EMT) via fascin-
induced E-cadherin/β-catenin system alterations that are 
responsible for nuclear shuttling of non-mutated β-catenin 
has been documented in a subset of LCNEC and SCLC 
(159-161). A further level of complexity in the molecular 
heterogeneity of Lu-NETs is unraveled by differences in 
gene expression profiling or diverse expression of functional 
biomarkers, such as CD44, orthopedia transcription 
factor, CEACAM and vitamin D-binding protein, which 
are able to identify patient subsets differentially at risk of 
progression within each histological variant or tumor group 
(52,54-56,97,159,162).
Molecular alterations of T-NETs are poorly understood 
and, in particular, only few next generation sequencing 
(NGS) studies have been conducted. In these tumors, 
MEN1 genotype/phenotype correlation is less significant 
than in Lu-NETs suggesting the involvement of other 
genetic factors (15,17,18,20,21). As a matter of fact, about 
one fourth of T-NETs are MEN1-related (20,163), whereas 
only 1–8% of patients with MEN1 syndrome develop 
T-NET during life (15,17,18,163-167). Most of MEN1-
related T-NETs correspond to carcinoids (163), but even 
poorly differentiated NE carcinomas (18,168) or purported 
carcinoids with gross areas of necrosis (15) have been 
reported. Interestingly, two T-NET cases have recently 
been reported, in which synchronous or metachronous 
LCNEC arose within a background of preexisting AC. All 
tumor components, either AC or LCNEC, presented with 
CTNNB1 mutations, which were likely responsible for 
cyclin D1-RB1 axis-dependent tumor growth, along with 
subsequent TP53 and JAK3 mutations in one case and EMT 
activation in the other case leading to de-differentiation and 
further tumor expansion (23). Chromosomal imbalances, 
whether loss or gain (95,169,170), and aneuploidy (171) 
are differentially distributed among the diverse subtypes 
of T-NETs, with the mean number of chromosomal 
imbalances being 0.8, 1.1 and 4.7 in TC (31% aberrant 
cases), AC (44% aberrant cases) and high-grade T-NET 
(75% aberrant cases), respectively. Gains of 8q24 mapping 
to MYC gene locus was the most frequent alteration and 
one of the overlapping features between carcinoids and 
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high-grade T-NENs (95).
Molecular alterations across Lu-NETs, T-NETs or 
GEP-NENs, yet with different prevalence rates, have 
recently been documented as mutations, copy number 
variations and microRNAs (24-27,95,157), thus supporting 
innovative insights into the developmental mechanisms of 
these tumors. The existence of combined variants of NETs 
in several anatomical locations (1,113) and experimental 
models on the development of secondary SCLC (158) reveal 
a high plasticity of cancer stem cells through the activation 
of multiple genetic and epigenetic mechanisms. It could be 
hypothesized that the occurrence of common genetic events 
among diversely classified tumors is functional to maintain 
shared biological, morphological or functional traits and/
or that even low grade tumors with well differentiated 
morphology have a potential to evolve into high-grade 
NETs (23). Interestingly, Lu-NETs, T-NETs and even 
GEP NENs with dual components of high- and low-grade 
tumors in synchronous or metachronous lesions have been 
identified (23,40,171-178). Further, these tumors share 
molecular alterations indicative of an origin from common 
ancestors of lower grade, with additional gene mutations 
occurring in the high-grade components over time due to 
temporally delayed clonal evolution of tumor cells. This 
combination of low-grade and high-grade components 
has been documented in the thymus (23,173,174) as 
secondary high-grade NETs, in the lung as NE carcinoma 
with carcinoid morphology (172) or carcinoids with 
proliferation rate progression (179), and in the GEP tract 
as transformed NET, well differentiated NET featuring 
high-grade components or well differentiated NET with 
high-grade (G3) progression (180,181). This concept, 
which would represent a paradigm shift from accepted 
pathogenesis schemes, has not been included in the current 
WHO classification of Lu-NETs where carcinoids or 
NETs are not thought to be usual early forerunners of 
high-grade lesions (1) and is probably an under-recognized 
phenomenon in these tumors. The reverse, i.e., down-
grading of poorly differentiated NETs, is not supported 
by the clinical behavior of these tumors (usually more 
aggressive than lower grade counterparts but less lethal 
than high-grade tumors) and by the occurrence of the same 
molecular alterations in both tumor components alongside 
further aberrations in high-grade elements promoting 
tumor dedifferentiation, growth and invasion (23). The 
recently described categories of NET G3 within the GEP 
tract (113,180) with a preserved well-differentiated NE 
morphology yet showing a mitotic count above 20 mitoses 
per 2 mm2 and Ki-67 LI over 20%, the carcinoid-like 
LCNEC and NE carcinoma with carcinoid morphology 
(40,172), and synchronous or metachronous thymus 
LCNEC retaining AC components (23) are instances of 
secondary high-grade NETs (23) derived from preexisting 
G1/G2 GEP NETs or lung and thymus TC/AT. CTNNB1 
gene mutations could be one of the molecular alterations 
underlying the progression in the thymus (23) and GEP 
tract (26). Similar occurrences, however, have been 
documented in secondary glioblastoma from long-standing 
astrocytoma (182,183) or triple negative breast cancer from 
adenoid cystic carcinoma (184). 
The hallmark of such secondary high-grade NETs in the 
thymus (23) and GEP tract (NV, personal communication) 
is the presence of concurrent and variably intermingled areas 
with low or high Ki-67 LI/mitotic counts within a tumor. 
These evolving tumors would be usually associated with 
an intermediate clinical course (23,181), unless additional, 
adverse molecular alterations, such as TP53 inactivation, 
took place over time (23). An instance of such a tumor 
arising in the lung is depicted in Figure 1, which emphasizes 
once again the role of Ki-67 LI for diagnosis and biological 
interpretation. This heterogeneous intra-tumor distribution 
of Ki67 LI likely results from diversely tuned cell subsets 
causing hot and cold spot areas to appear within individual 
tumors. Heterogeneity of Ki-67 LI at metastatic sites and 
among different metastasis locations as compared with paired 
primaries was first described in pancreatic NETs (120), 
but has recently been indicated to occur in stage IV lung 
carcinoids only in an abstract form (179).
At this point, the clinical and biological questions are 
related to the frequency of this event and to the level of 
diagnostic awareness by pathologists. It has been observed 
that carcinoids and high-grade NE carcinomas in the 
lung share most of the altered genes, such as mutations, 
copy number variations and microRNA, even though at 
different prevalence (24-27,95,157), and that common 
mutations or chromosomal changes may unexpectedly 
cluster tumor regardless of histology. This supports a 
transition from low to high grade in a non-negligible 
fraction of Lu-NETs (GP, personal experience). To partly 
explain the apparent contradiction to the widely reported 
differential distribution of molecular events among diverse 
NETs in both the lung and elsewhere (1,50,92,95), it 
should be kept in mind that most of existing molecular 
data have been derived from the analysis of surgical 
specimens, where up to one fourth/one third of high-
grade NET patients experience longer survival (56). 
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Figure 1 An example of secondary high-grade neuroendocrine tumor of the lung is depicted according to conventional staining and IHC 
markers (×200). The lower grade component (A) is composed by carcinoid with no obvious mitoses or necrosis spots, whereas the high-
grade component (accounting for more than 50% tumor mass) featured small cells with numerous mitotic figures (yellow asterisks) (B). The 
lower grade component was positive diffusely for cytokeratin cocktail AE1-AE3 (C), chromogranin A (D), and showed low Ki-67 labeling 
index (about 15%) (E), with transition areas towards higher grade elements (E, inset). In turn, the high-grade component showed faint 
decoration for cytokeratin with paranuclear dot-like quality (F) and chromogranin A (G), while Ki-67 labeling index turned out to be very 
high (about 60%) (H). No differences were instead observed for synaptophysin labeling between the two cell components (D and G, insets). 
IHC, immunohistochemistry.
A B C
FD E
G H
This implies that histologically poorly differentiated 
neoplasms amenable of complete resection and running a 
more favorable clinical course could harbor these evolving 
secondary high-grade NE tumors. It will be essential to 
clarify if these tumors correspond to progressing lesions, 
which are in turn highlighted by heterogenous Ki-67 LI, in 
order to understand their pathological basis and explore the 
most appropriate clinical management.
Conclusions
Our understanding of Lu-NET is rapidly expanding, 
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especially regarding diagnosis, IHC marker choice 
and pathogenetic mechanisms, although adapting the 
morphology-based classification to the personalized and 
precision medicine is still challenging. This holds true 
in NETs of other organs as well. The assumption of 
differential genomic alterations between well-differentiated 
NE tumors and high-grade NE carcinomas of the lung 
and thymus is substantiated by multiple studies, but 
reassembling the existing data under the concept of 
secondary high-grade NETs has led to a possible paradigm 
shift in the pathogenesis of NETs.
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